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Abstract
Although studies have suggested that a patient’s perceived cost-benefit of a medical intervention
could affect his or her utilization of the intervention, the economic value of influenza vaccine from
the patient’s perspective remains unclear. Therefore, we developed a stochastic decision analytic
computer model representing an adult’s decision of whether to get vaccinated. Different scenarios
explored the impact of the patient being insured versus uninsured, influenza attack rate, vaccine
administration costs and vaccination time costs. Results indicated that cost of avoiding influenza
was fairly low, with one driver being required vaccination time. To encourage vaccination,
decision makers may want to focus on ways to reduce this time, such as vaccinating at work,
churches, or other normally frequented locations.
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Vaccination coverage for influenza among adults has remained well below the desired rates
set forth in Healthy People 2010.[1–2] Approximately 32% of the general public and less
than 70% of high risk groups identified by the Advisory Committee on Immunization
Practices (ACIP) reported being vaccinated against influenza during the 2008–2009 flu
season.[1–2] The monovalent 2009 H1N1 influenza vaccine experienced particularly poor
uptake, as approximately 80% of the U.S. population remained unvaccinated.[3]
Misinformation and lack of knowledge regarding vaccine safety, effectiveness and
importance, as well as challenges of cost, location and time have been frequently identified
as barriers to achieving higher coverage.[4–6]
While studies have quantified the economic value of influenza vaccination from the societal
and third party payor perspectives in a variety of patient populations, few have addressed the
economic value of vaccination from the perspective of individual patients.[7–10] Although
it is unlikely that patients base their decisions about vaccination purely on economic
considerations, better understanding a vaccine’s economic value to patients can assist
various types of decision-making. Studies have demonstrated that a patient’s perceived cost-
benefit of a medical intervention can affect his or her utilization of the intervention, i.e.,
medical intervention utilization is fairly price elastic.[11–12] For example, pharmacy
copayment increases have been paralleled by reductions in patient use of psychiatric and
cardiovascular medications.[13–14] Conversely, decreases in required copayments have
been followed by increased utilization of antibiotics.[15–19] A recent survey suggested that
higher vaccine cost may dissuade adults from getting vaccinated.[12] As a result, the Task
Force on Community Preventive Services recommends reducing client out-of-pocket costs
as a means of enhancing access to vaccination services and increasing vaccination coverage.
[20]
Therefore, better understanding the costs of vaccination for a patient could be useful for
various decision makers associated with vaccination efforts. Health care workers and public
health officials may use the information to convey the advantages and disadvantages of
vaccination to patients. It could also serve as the basis for vaccine pricing, third party
coverage, incentive, and various cost-sharing decisions. For instance, identifying disparities
in the economic value for under- or uninsured patients may motivate programs to alleviate
their financial burden in getting vaccinated. Value-based insurance design, the idea of
promoting the use of a service (such as preventive influenza vaccination)—through lower or
no cost immunization—when the clinical benefits exceed its cost, is an approach that may
help improve vaccine coverage. Ascertaining the drivers of patient cost can help to identify
operations structures and policies amenable to intervention.
To delineate the economic value of influenza vaccination from the adult (between 18 and 49
years old) patient perspective, we developed a computer simulation model representing the
decision to get vaccinated. Different scenarios explored the impact of the patient being




Using TreeAge Pro 2009 (TreeAge Software, Williamstown, Massachusetts), we developed
a decision analytic computer simulation model representing an individual’s decision of
whether to get vaccinated against influenza. The model focused on standard-risk adults (i.e.,
not high-risk by ACIP definitions), who comprise the majority of individuals in the 18 to 49
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year old population and are eligible for both the TIV and LAIV vaccines. Outcomes data for
the models came from an extensive literature review, using the following search terms:
[seasonal AND influenza], [2009 H1N1], [influenza AND vaccination], [influenza AND
vaccination AND cost], [influenza AND outcomes], and [influenza AND vaccination AND
side effects]. The authors judged each article critically on study design and relevance to our
target population. Separate scenarios assumed that the patient had commercial insurance or
was uninsured. Additional scenarios examined the use of tetravalent inactivated vaccine
(TIV) versus live attenuated influenza vaccine (LAIV). Figures 1 and 2 depict the general
structure and influenza outcomes subtree of the model, respectively, which assumed a
patient perspective.
Patients who received the vaccine then had probabilities of experiencing major or minor side
effects or both. Minor side effects included local inflammation or minor systemic flu-like
symptoms, requiring self-treatment with ibuprofen. Guillian-Barré Syndrome (GBS), an
autoimmune disorder of the peripheral nervous system, was the only major side effect
considered; all cost and probability data relating to major side effects from vaccination in
the model were therefore GBS- specific. The risk of developing symptomatic influenza
depended on the clinical attack rate and whether the patient received a vaccine. Vaccination
attenuated the risk of influenza by an amount determined by vaccine efficacy. A patient who
developed symptomatic influenza then proceeded through the influenza outcomes sub-tree
(Figure 2). A symptomatic patient had a probability of visiting a medical clinic, being
hospitalized, requiring admission to the intensive care unit (ICU), and not surviving.
Symptomatic patients that did not interface with the health care system relied on over-the-
counter medications. Of the patients who visited a clinic, half (50%) received antiviral
medication treatment.
Patient costs originated from three sources:
• Productivity/Wage Loss: Getting vaccinated, contracting symptomatic influenza,
and hospitalization each incurred unique durations of time off from work.
Productivity losses were equivalent to the wages that the patient could have earned
during the required time off from work.
• Medication/Treatment Costs: Vaccines cost the patient money. Symptomatic
patients purchased over-the-counter medications. Half of all patients who visited
the clinic paid for prescription antivirals. Prescription medication and vaccine costs
depended on the patient’s insurance status
• Health Care Costs: Patient payments for clinic visits, hospitalization, and ICU stays
depended on the patient’s insurance status.
For each simulation run, the equation below computed the cost per influenza case averted by
the vaccine:
(1)
The following equation calculated the cost per influenza death averted by the vaccine:
(2)
2.2 Data Inputs
Table 1 organizes the data inputs for our model into costs, probabilities, and relevant time
durations and lists their ranges and distributions. Cost and efficacy parameters were specific
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to the type of vaccine. Table 1 also lists the sources of each parameter input. The amounts
paid by each individual depended on his or her insurance type, where uninsured patients had
to cover medical costs (not charges).[21] Hospitalization costs came from the healthcare
utilization project’s (HCUP) national inpatient survey (state inpatient data from Arizona,
Florida, Massachusetts, Maryland, New Jersey, New York, Texas and Washington), using
ICD-9 codes 480 and 357 for hospitalization and ICU admittance from influenza and major
side effects such as Guillain-Barré respectively. Clinic costs originated from the Centers for
Medicare and Medicaid Services (CMS). Medication costs were derived from their average
wholesale prices, as drawn from the PDR Red Book.[22] The 2008 national median wage,
retrieved from the Bureau of Labor and Statistics, was used to create a distribution of daily
wages.[23]
By contrast, the model made the following assumptions about the commercially insured
based on benefit design information obtained from the Henry J. Kaiser Family Foundation,
Health Research & Educational Trust Survey of Employer-Sponsored Health Benefits, 2009:
• 36.3% had no annual deductible [24]
• The distribution of plan types was as follows: 20% health maintenance organization
(HMO), 60% preferred provider organization (PPO), 10% point of service (POS),
and 10% high deductible health plan (HDHP/SO) [24]
• 18% of those with no deductible had coinsurance [24]
• Those who paid a deductible (63.7%) paid $809.90. [24]
Based on a report using data collected through the Medical Expenditure Panel Surveys,
uninsured individuals paid approximately one third of their total medical costs. [25] All
costs were expressed in 2009 U.S. dollars with a 3% discount rate converting costs from
other years.
2.3 Sensitivity Analyses
Probabilistic (first and second-order) sensitivity analyses with microsimulation
simultaneously varied the values of each variable across the ranges listed in Table 1, i.e.,
each parameter value from distributions listed in Table 1 and then individuals proceeded
down each branch of the tree based on stochastic dice rolls against the probability values
drawn from the distributions. Specific analyses explored the effects of ranging vaccination
cost, which included both the cost of vaccine and other ancillary costs (i.e., travel and/or
childcare expenses). We utilized a baseline cost of $15 (TIV) and $25 (LAIV) for scenarios
where vaccination costs were equivalent to only that the vaccine itself as well as $0, $50,
and $150 for both TIV and LAIV. The $0 vaccination cost accounts for scenarios where
vaccine may be administered during a routine visit and does not incur an additional cost;
higher vaccine costs ($50 and $150) allow for the inclusion of potential transportation costs
needed to get to a health care facility. We additionally varied the hours missed from work to
get vaccinated (1 hour to 4 hours), the probability of major vaccine side effects (i.e.,
Guillain-Barré), the clinical attack rate of influenza, and the probability of influenza
resulting in a hospital and ICU admission.
Baseline attack rates for seasonal influenza drew from a beta distribution (estimated from a
mean of 6.6% and standard deviation of 1.7%). One-way sensitivity analyses also evaluated
ranging this attack rate from flat values of 2% up to 15%.[26–27] As limited U.S based data
exists regarding the incidence of 2009 H1N1 during the 2009–2010 influenza season, the
H1N1 baseline attack rate for the US was estimated using a seroprevalence reports
conducted in England during this time period; additional simulations utilized an attack rate
of 6.5%, which is comparable to incidence given in a brief U.S. based report.[28–29] While
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baseline influenza risks were drawn from studies reporting data from a limited number of
influenza seasons, these distributions of influenza risk are likely the most probable. Varying
the attack rate higher and lower than these expected distributions was not meant to represent
a likely risk of flu, but was instead intended to quantitatively illustrate the effect of an
increased or decreased risk of influenza on the cost of avoiding a case of influenza by
vaccination. For seasonal flu, the probability of ICU admittance ranged from 5% to 20%; the
probability of ICU care being received as a result of H1N1 ranged from 15% to 25%. Two
case fatality rates for H1N1 were evaluated; the first distribution (triangular, likeliest value:
0.16% range: 0.066–0.333%) was based on the symptomatic influenza-specific case fatality,
while the second was a case fatality rate (triangular, likeliest value: 0.01% range: 0.007–
0.016%) calculated out of the overall self-reported symptomatic influenza-like illness
reports.[30] Baseline runs used 0.002% and 0.0003% for the probability of major side
effects from LAIV and TIV vaccines respectively.[31–32] Additional analyses examined the
effects of doubling the probability of ICU admittance and major side effects.
3. RESULTS
3.1 Simulation Parameters
The median age used in the model was 30 years for uninsured patients and 40 years for
commercially insured patients. Additional analyses evaluated ages 40 and 49 for uninsured
and commercially insured populations, respectively, as 49 is the oldest age at which
administering LAIV is still recommended. Median age data was generated with data from
the Bureau of Labor and Statistics and a recent paper on the cost and coverage of healthcare
among the uninsured.[25,33] Each simulation run sent 1,000 hypothetical individuals, each
with a unique set of characteristics (each individual drew from the wage distribution to
represent the diversity of jobs, geographic locations, and sociodemographic characteristics
that may affect wages; those who developed side effects drew from the cost of side effects
distribution and those who became ill drew from the clinic and hospitalization cost
distributions to reflect the sociodemographic and clinical diversity that exists among adults),
through the model 1,000 times for a total of 1,000,000 patient outcomes for each simulation
run. (Note: the parameters drew independently from each respective distribution and were
not correlated.)
3.2 Measurements of Stochasticity
Tornado diagrams in Figure 3 demonstrate the impact that each variable included in our
sensitivity analysis has on the incremental cost per averted case. As shown in the figure,
ranging vaccination cost, the time needed for vaccination, and attack rate had the most
impact on the incremental cost for all scenarios, with vaccination cost having the greatest
effect; the probability of ICU or mortality from influenza and the probability of major
vaccine side effects had little to no impact on the cost averted by preventing an influenza
case.
Scatter plots (see Supplementary Figure 1) depict the variability of cost and influenza
occurrence within a particular simulation. While vaccinating was associated with higher cost
compared to no vaccination, the vaccination group had substantially fewer influenza cases as
well as lower variation in influenza occurrence. Relatively little difference in cost and
influenza cases was observed between the commercial insurance and uninsured groups for
both H1N1 and seasonal influenza. Seasonal influenza scenarios illustrated a lower variation
in the occurrence of influenza in the no vaccination group (but not in the vaccination group),
which is likely a product of a narrower attack rate baseline distribution (see Table 1).
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3.3 Seasonal Influenza Scenario
Table 2 presents the median and 95% confidence interval (both 2.5th and 97.5th percentiles)
for the cost per averted influenza case from our seasonal influenza model assuming a 15%
baseline probability of ICU (given hospitalization) as well as a 0.0003% and 0.002%
probability of major side effects from TIV and LAIV vaccine formulations, respectively. As
mentioned above, the value of vaccination was fairly sensitive to vaccination cost, the time
required for vaccination, and influenza attack rate. When vaccination took no more than one
hour, TIV generated marginal (when compared to no vaccination) costs only slightly higher
than that of the vaccine itself (approximately $27 for seasonal influenza vaccine and $17 for
H1N1 vaccine) shown in Figure 4.
A 4 hour vaccination administration time, which would correspond to a patient traveling to a
physician’s clinic, was almost three times as expensive as a one-hour administration time,
which may correspond to a patient traveling to either a closer location or a location that has
less of a wait time (e.g., a dedicated immunization clinic). Although varying vaccination
costs over the range explored in the sensitivity analyses had the greatest effect on the
economic benefit of vaccination, a slight increase in influenza attack rate results in a greater
impact on vaccination benefit. For example, while increasing attack rate from baseline to
15% (approximately 2 times the mean at baseline) resulted in a 3 fold decrease in the cost of
averting an influenza case, increasing vaccination cost by the same amount (from $25 to
$50) resulted in a 2 fold increase in cost per averted case (see Table 2).
TIV consistently provided greater economic value than LAIV, as the added efficacy of
LAIV did not overcome the higher cost of the vaccine. The economic value of vaccination
was fairly comparable for insured and uninsured patients, mainly because influenza
hospitalization was relatively infrequent among adults and insurance status had little impact
on the cost of over-the-counter medications and missing work.
3.4 2009 H1N1 Influenza
H1N1 vaccination provided relatively more economic benefit than seasonal influenza
vaccination, mainly because H1N1 had slightly higher morbidity and mortality than seasonal
influenza among the younger adult population (i.e., the population that comprises much of
the commercially insured and uninsured). Table 3 demonstrates the effect of vaccine cost,
administration time, and attack rate on the median cost of avoiding an influenza case, where
baseline probability of H1N1 influenza was a triangular distribution (min=6.5%, likeliest=
11.5%, max=19.4%) ICU from H1N1 (given hospitalization) = 20%, case fatality rate was a
triangular distribution (min= 0.007%, likeliest= 0.01%, max= 0.016%), and the probabilities
of major side effects from TIV and LAIV vaccine formulations were 0.0003% and 0.002%,
respectively. While the economic benefit of vaccination was comparably dependent on both
the time off from work needed for vaccination and influenza attack rate, varying vaccine
cost over the range evaluated through sensitivity analyses had the greatest effect on the cost
averted by vaccination. However, as with seasonal influenza vaccination, a greater impact
results with decreased influenza risk than with increased vaccination cost of similar
magnitude. No significant difference was present between insured and uninsured
individuals. Hospitalization rates for H1N1 influenza were still not high enough to result in
differences by insurance status. Additionally, there was little difference between the LAIV
and TIV vaccines even if the individual were responsible for higher total vaccination costs
(vaccine costs for the 2009 H1N1 vaccination program were fully subsidized by the federal
government.
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Compared to the number of published studies from the societal and third party payor
perspectives, relatively few economic studies have looked at medical interventions from the
patient perspective. The vast majority of health economic studies focus on the societal
perspective, summing costs across all key stakeholders, or have evaluated whether a large
policy-making entity (e.g., government) should make an intervention available or a third
party payor (e.g., Medicare or commercial insurance) should cover an intervention.
However, when the objective is to increase historically low influenza vaccination rates,
accounting for only these two perspectives is myopic and may fail to account for key driving
forces or stakeholders. Cost is certainly not the only (or even the primary) factor in a
patient’s decision to get vaccinated, but its role is salient. As direct-to-consumer marketing
grows more pervasive in health care, the patient economic perspective may be increasing in
importance.
A trend over the past two decades has been casting patients as “consumers,” who must
choose among goods or interventions offered by traditional and non-traditional health care
providers.[34] Commercials and advertisements tout the “value” of health care goods and
services. While this value is sometimes quantified in terms of clinical efficacy, it is often not
quantified monetarily. In many other situations where consumers have a choice (e.g.,
purchasing automobiles, food, or clothing), understanding the economic value of a good or
service from the consumer’s perspective can help both the consumers and providers of the
good or service. Consumers may realize that a good is either more or less valuable than
anticipated, which may in turn affect their decision-making (e.g., is it worthwhile to miss
work to get vaccinated). Providers may be able to tailor the good or service to assist the
consumer (e.g., making it more convenient for patients to get vaccinated or adjusting the
price of the vaccine).
Although economic indicators and models cannot fully capture all the advantages and
disadvantages of a medical intervention, they can offer important benchmarks, perspectives,
and insights. In our model, the strongest drivers of the vaccine’s economic value were the
clinical attack rate followed by vaccination cost and the time required (i.e. lost productivity)
by the individual to get vaccinated. This suggests that in a seasonal or a relatively mild
pandemic scenario such as the 2009 H1N1 pandemic, making influenza vaccination less
costly and more convenient may be an important priority and prerequisite for improved
vaccination coverage.[4,35–36] For example, providing vaccination at locations the patient
already frequents (e.g., work, churches, retail shops and clinics, concerts, athletic events,
and other public gatherings) may be a useful cost-saving measure for individuals.
Alternatively, in more severe epidemics, making a special trip and queuing for vaccination
may be relatively less costly for an individual.
The relative parity in cost of vaccination observed between uninsured and insured
individuals is informative as well. Finding a significant difference between the two would be
expected based on reports that insurance status often dictates the decision to get vaccinated,
and also would suggest that more tailored approaches to promote vaccination in each group
may be needed.[4,37] Instead, the two groups seem to be facing similar costs for
vaccination, i.e., lack of insurance coverage may not actually be a barrier for vaccination.
4.1 Limitations
All computer models make simplifying assumptions and cannot represent all possible
outcomes that may arise from influenza vaccination or disease. Additionally, they cannot
account for the vast diversity in the socio-demographic and health characteristics of the adult
population. Our model only considered the healthy adult population which comprises the
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majority of the population. High-risk individuals (e.g., those with major co-morbidities such
as diabetes, pregnant women, or health care workers) may either have higher risk for
influenza-associated morbidity and, therefore, could reap more benefits (i.e., greater cost-
savings) from vaccination or could have additional reasons for being immunized (e.g.,
protecting neonates or patients). Future studies may focus on different categories of high-
risk individuals. Although all data came from referenced sources identified from an
extensive review of the literature and widely-used databases, the choice of probability
distributions could bias the results. Costs drew from gamma distributions, frequently utilized
for health care related costs that tend to cluster in the lower end of the distribution and have
relatively fewer higher costs trail off into the upper tail. Probability parameters drew from
beta distributions, frequently used to represent continuous variables that have values
between 0 and 1. Lastly, parameters with relatively sparse observations drew from triangular
distributions, built from a minimum, maximum, and likeliest value.[38–39] Moreover, it is
difficult to quantify (both monetarily and in terms of health benefits) all facets of vaccine
value, such as convenience, patient preference (for either injection or nasal spray, where
indicated) and comfort, and the relative worth of LAIV and TIV for all scenarios. The
decision to get the influenza vaccine and the type of vaccine administered should be
determined on a case-by-case basis.
4.2 Conclusions and Future Directions
Understanding the cost-benefit of vaccination from the patient perspective can provide
interesting insights for vaccination policy. While cost is certainly not the only driving factor
in a patient’s decision to get vaccinated, studies have suggested that a patient’s perceived
cost-benefit of a medical intervention could affect his or her utilization of the intervention.
Aside from vaccine cost and attack rate, one of the biggest drivers of vaccination costs was a
patient’s time required for vaccination, so decision makers may want to focus on ways to
reduce this time, such as bringing vaccination to individuals (e.g., at work, churches, or
other normally frequented locations). Ideally, reducing the time demand and cost of
immunization for patients will help improve influenza vaccine coverage.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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General structure of the decision model. a Includes local inflammation or minor systemic
flu-like symptoms, requiring self-treatment with ibuprofen. b Guillian-Barré Syndrome
(GBS)
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a–d: Tornado Diagrams. a–b H1N1 vaccination scenarios for commercially insured (a) and
uninsured (b) groups; c–d seasonal influenza vaccination scenarios for commercially insured
(c) and uninsured (d) groups. The central axis represents the resulting incremental cost per
averted influenza case when all parameters listed were set to their midpoint value of their
explored ranges: vaccine cost (range: $0 – $150), attack rate (range: 6.5%–12.5% for H1N1
and 2%–15% for seasonal influenza), time needed for vaccination (range: 1–4 hours), major
vaccine side effects (range: 0.0003%–0.0006%), ICU from influenza (15%–25% for H1N1
and 5%–20% for seasonal influenza), case fatality rate (0.011%–0.186% for H1N1). Table 1
shows baseline values for each parameter. The dashed vertical line marks where the
incremental cost per averted case = 0. Negative incremental costs occurred when vaccination
was economically dominant compared to no vaccination.
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Comparison of median costs for influenza vaccination with 95% confidence interval (2.5th
and 97.5th percentiles between uninsured and commercially insured patients for (A) seasonal
influenza and (B) 2009 H1N1 influenza. This data assumes a clinical attack rate of 10%,
TIV cost of $15, and baseline probabilities shown in Table 1. Negative values indicate cost-
savings. * 2.5th percentile = −20.9 ** 2.5th percentile = −7.01 *** 2.5th percentile = −7.78
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